NCT02962440View on ClinicalTrials.gov

A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Healthy

Interventions

DRUG

somapacitan

All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing \[3H\]-somapacitan

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

Novo Nordisk A/S

All Listed Sponsors

lead

Novo Nordisk A/S

INDUSTRY